Goodfellas star Ray Liotta’s new line? A quit-smoking pitch for Pfizer’s ChantixAllbiopro2018-07-09T10:09:13+09:007월 9th, 2018|
GE Considers Broadening ‘Brilliant’ Approach to Media ManufacturingAllbiopro2018-07-09T10:08:46+09:007월 9th, 2018|
FiercePharmaAsia—Sanofi’s Chengdu R&D hub, Takeda’s Osaka HQ sale, I-Mab’s $220M financingAllbiopro2018-07-09T10:08:18+09:007월 9th, 2018|
Chutes & Ladders—Ex-Millennium chief Deborah Dunsire named CEO of LundbeckAllbiopro2018-07-09T10:07:24+09:007월 9th, 2018|
Bristol-Myers Squibb looks to sell French OTC unit which could bring $1.8B: reportAllbiopro2018-07-09T10:06:57+09:007월 9th, 2018|
Biogen Shares Positive Results in Alzheimer’s Phase II TrialAllbiopro2018-07-09T10:06:32+09:007월 9th, 2018|
Biogen and Eisai’s previously bleak Alzheimer’s study comes back with positive resultsAllbiopro2018-07-09T10:06:05+09:007월 9th, 2018|
Bacteria-powered solar cell converts light to energy, even under overcast skiesAllbiopro2018-07-09T10:05:38+09:007월 9th, 2018|
After breathing new life into old mice, senescence startup Cleara bags cash to move toward the clinicAllbiopro2018-07-09T10:05:11+09:007월 9th, 2018|
Trump’s U.K. visit sparks plans for mass protests—and dinner invites for GSK, J&J CEOs: FTAllbiopro2018-07-06T12:14:31+09:007월 6th, 2018|
Takeda’s Osaka headquarters up for sale as drugmaker funds $62B Shire buyout: reportAllbiopro2018-07-06T12:14:04+09:007월 6th, 2018|
Jefferies says Gilead is poised for turnaround—and JAK inhibitor could be keyAllbiopro2018-07-06T12:13:37+09:007월 6th, 2018|
Ironwood’s preparation for activist-driven R&D split puts 40 staffers out of workAllbiopro2018-07-06T12:13:11+09:007월 6th, 2018|
ICER to payers: Go easy on CGRP restrictions if pricing stays reasonableAllbiopro2018-07-06T12:12:46+09:007월 6th, 2018|
